Included in the formulation
Included in the list (Order of the Government of the Russian Federation No. 2782-r of 30.12.2014):ONLS
АТХ:D.01.B.A Antifungal drugs for systemic use
J.02.A.X.06 Anidulafungin
Pharmacodynamics:Semisynthetic echinocandin synthesized Aspergillus nidulans. It has fungicidal action due to suppression of the enzyme (glucosynthesis) involved in the construction of a fungal cell.
Active with respect to Candida albicans, Candida glabrata, Candida parapsilosis, Candida tropicalis, and Candida spp.
Pharmacokinetics:The clearance of anidulafungin is 1 liter per hour. Half-life is 24 hours. The terminal half-life is 40-60 hours. It binds to blood plasma proteins - over 99%. The liver is not metabolized. It is not dialyzed.
Elimination with bile and feces. A small amount - about 1% - by the kidneys.
Indications:It is used in the treatment of invasive candidiasis, including infection associated with the human immunodeficiency virus.
I.B35-B49.B37.7 Candida septicemia
I.B20-B24.B20.4 The disease caused by HIV, with manifestations of candidiasis
I.B35-B49.B37.8 Candidiasis of other localizations
I.B35-B49.B37.9 Candidiasis, unspecified
Contraindications:Individual intolerance of anidulafungin and other drugs from the class of ekinokandidov.
Carefully:Used with caution in patients with hepatic insufficiency. With deviations in laboratory indicators (growth aspartate aminotransferase, alanine aminotransferase) the dose of anidulafungin is adjusted.
Pregnancy and lactation:Pregnancy and lactation: recommendations for Food and Drug Administration (US Food and Drug Administration) - Category C. The use of anidulafungin during pregnancy can be justified only in cases where the expected effect exceeds the possible risk to the fetus. There is no evidence of ingestion into breast milk - it is recommended to stop breastfeeding during treatment.
Dosing and Administration:It is used to treat immunocompromised children: at the age of 2-11 years - at 0.75 mg / kg per day and 50-100 mg per day - from 2 to 17 years.
Introduced intravenously drip with a speed of not more than 1.1 mg per minute. On the first day, a single loading dose of 200 mg is given. Then, 100 mg daily is administered. The course of treatment is at least 14 days. The dose is adjusted depending on the effect of therapy.
The highest daily dose: 200 mg.
The highest single dose: 200 mg.
Side effects:Blood coagulation system: coagulopathy.
Nervous system: headache, convulsions.
Cardiovascular system: hyperemia of the face, hot flushes.
Digestive system: vomiting, diarrhea, increased alanine aminotransferase, aspartate aminotransferase, bilirubin of blood.
Skin: itching, rash.
Allergic reactions.
Overdose:When the drug was administered in an amount of 400 mg, no clinical side effects were noted.
Interaction:At simultaneous reception of a preparation in therapeutic doses clinically significant changes it is not revealed.
Enhancement of adverse reactions was noted with the simultaneous use of anidulafungin with anesthetics.
Special instructions:Before the introduction of the drug, it is recommended that laboratory tests, including histopathological tests, be conducted to identify the type of pathogen. Treatment can be initiated before receiving the results of the studies with subsequent therapeutic correction.